Alluvi tirzepatide appears to have emerged as a promising therapeutic candidate for the management of metabolic diseases. This exploratory evaluation investigated the efficacy and safety of tirzepatide 40mg in animal models of metabolic syndrome. The studies demonstrated that tirzepatide 40mg substantially enhanced glycemic regulation and decreased